转移性透明细胞肾细胞癌患者病理因素与索拉非尼治疗疗效的关系
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
作者信息
Araki Hidemori, Tsuzuki Toyonori, Kimura Tohru, Tanaka Kuniaki, Yamada Shin, Sassa Naoto, Yoshino Yasushi, Hattori Ryohei, Gotoh Momokazu
机构信息
From the Department of Urology, Toyohashi Municipal Hospital, Toyohashi, Japan;
Department of Pathology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan;
出版信息
Am J Clin Pathol. 2015 Apr;143(4):492-9. doi: 10.1309/AJCPM8RJ2ECAWOGQ.
OBJECTIVES
To evaluate the predictive value of growth patterns in patients undergoing sorafenib treatment for metastatic clear cell renal cell carcinomas (CCRCCs).
METHODS
Forty-eight patients were analyzed, each of whom underwent nephrectomy and received sorafenib treatment for metastatic CCRCC. Progression-free survival (PFS) was predicted using pathologic parameters, including pathologic stage, Fuhrman nuclear grade (FNG), the presence of a sarcomatoid component, lymphovascular invasion, tumor necrosis, and growth pattern.
RESULTS
Three (6%) patients showed partial response, 20 (42%) patients showed stable disease, and 25 (52%) patients showed progressive disease. Univariate analyses demonstrated that FNG, the presence of a sarcomatoid component, tumor necrosis, and growth pattern were significantly associated with PFS. In the multivariate analysis, growth pattern was the only parameter that was significantly and independently predictive of PFS.
CONCLUSIONS
As a novel histologic prognostic parameter, growth pattern may be useful for predicting response to sorafenib treatment.
目的
评估索拉非尼治疗转移性透明细胞肾细胞癌（CCRCC）患者时生长模式的预测价值。
方法
分析48例患者，每位患者均接受了肾切除术并接受索拉非尼治疗转移性CCRCC。使用病理参数预测无进展生存期（PFS），包括病理分期、富尔曼核分级（FNG）、肉瘤样成分的存在、淋巴管侵犯、肿瘤坏死和生长模式。
结果
3例（6%）患者出现部分缓解，20例（42%）患者疾病稳定，25例（52%）患者疾病进展。单因素分析表明，FNG、肉瘤样成分的存在、肿瘤坏死和生长模式与PFS显著相关。在多因素分析中，生长模式是唯一显著且独立预测PFS的参数。
结论
作为一种新的组织学预后参数，生长模式可能有助于预测索拉非尼治疗的反应。
Zotero 插件